First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, Hirakata, Japan.
Department of Emergency Medicine, Kansai Medical University Medical Center, Moriguchi, Japan.
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0106424. doi: 10.1128/aac.01064-24. Epub 2024 Aug 29.
We evaluated the efficacy of ensitrelvir for the treatment of cough due to coronavirus disease 2019 Omicron variant in medical healthcare workers. A total of 633 patients were registered in this study: 206 patients chose ensitrelvir and 427 patients chose symptomatic treatment. Difference in score changes using the Leicester Cough Questionnaire between groups was 3.17 on day 4, 3.24 on day 7, and 2.46 on day 14. The analysis demonstrated a significant difference at all time points.
我们评估了恩赛特韦在治疗因新冠病毒奥密克戎变异株感染而引起的咳嗽方面的疗效。共有 633 名医护人员参与了这项研究：206 名患者选择了恩赛特韦，427 名患者选择了对症治疗。莱斯特咳嗽问卷评分的组间变化差异在第 4 天为 3.17，第 7 天为 3.24，第 14 天为 2.46。分析表明所有时间点均存在显著差异。
